SAN DIEGO, April 23, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will webcast
its Quarterly Update Conference Call for the first quarter 2019 on
Tuesday, May 7 at 4:30 p.m. ET / 1:30 p.m.
PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the
same date, Halozyme will release financial results for the first
quarter ended March 31, 2019
following the close of trading.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit the
Investors page of www.halozyme.com approximately fifteen minutes
prior to the call to register, download and install any necessary
audio software. The live call may be accessed by dialing (866)
393-4306 (domestic callers) or (734) 385-2616
(international callers). A telephone replay will be available
after the call by dialing (855) 859-2056 (domestic callers) or
(404) 537-3406 (international callers) using replay ID number
3076769.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a
unique approach to targeting solid tumors, allowing increased
access of co-administered cancer drug therapies to the tumor in
animal models. PEGPH20 is currently in development for the
treatment of several cancers and has the potential to be used in
combination with different types of cancer therapies. In addition
to its proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical and
biotechnology companies, including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its
ENHANZE® drug delivery technology. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-host-first-quarter-2019-financial-results-webcast-and-conference-call-300836689.html
SOURCE Halozyme Therapeutics, Inc.